Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 5/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654667 | 0.90 | HTR7 (0.53) | MAPTTP53HTR1AHTR7 | |
| SCHEMBL5655916 | 0.87 | MAPT (0.50) | MAPTTP53HTR1ADRD2DRD4 | |
| SCHEMBL5656134 | 0.85 | HTR1A (0.48) | MAPTSMN1; SMN2HTR1AHTR7DRD4 | |
| SCHEMBL5656008 | 0.85 | HTR7 (0.54) | MAPTTP53SMN1; SMN2HTR1AHTR7 | |
| SCHEMBL6416890 | 0.84 | DRD2 (0.52) | MAPTTP53DRD2DRD4DRD3 | |
| SCHEMBL5657837 | 0.84 | HTR1A (0.56) | MAPTHTR1AHTR7DRD2DRD4 | |
| SCHEMBL6417708 | 0.83 | MAPT (0.43) | MAPTTP53SMN1; SMN2HTR1AHTR7 | |
| SCHEMBL5657971 | 0.83 | KCNH2 (0.50) | MAPTSMN1; SMN2HTR1AHTR7DRD2 | |
| SCHEMBL5657779 | 0.83 | HTR1A (0.59) | MAPTSMN1; SMN2HTR1AHTR7TSHR | |
| SCHEMBL6422498 | 0.82 | HTR7 (0.39) | MAPTTP53HTR1AHTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267126-A1 | Compounds derived from aryl carbamates, preparation thereof and uses of same | CEREP (FR) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267126-A1 | Compounds derived from aryl carbamates, preparation thereof and uses of same | HTR4, HTR2B, HTR1B | MAPT 3281/4885TP53 4475/4885SMN1; SMN2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.